Dosing & Administration9 min readUpdated 2026-08-07

    Missed Your Tirzepatide Dose? The 4-Day Rule (2026)

    Per FDA labeling, you have 4 days (96 hours) to take a missed tirzepatide dose — after that, skip it and resume your regular day. Day-by-day decision table, double-dose guidance, and restart rules.

    Important Medical Disclaimer

    This article summarizes FDA labeling for educational purposes and is not medical advice. Your prescription may come with different instructions — those, and your licensed provider's guidance, always take priority over anything written here. When a situation is ambiguous, message your provider before injecting.

    The Direct Answer: The 4-Day Rule

    Per FDA prescribing information for Zepbound and Mounjaro (tirzepatide), take a missed dose as soon as possible within 4 days — 96 hours — of your scheduled injection day. If more than 4 days have passed, skip the missed dose entirely and take your next dose on your regular day at your usual prescribed dose.

    Those two sentences resolve almost every missed-dose situation. The rest of this guide is the detail: a day-by-day decision table, how to shift your injection day safely, what a gap actually does inside your body, and the one scenario that deserves prompt attention — accidentally injecting twice. If you take semaglutide instead, note that its window is different; see our semaglutide missed dose guide.

    "as soon as possible within 4 days (96 hours) after the missed dose"
    — Zepbound (tirzepatide) Prescribing Information, Dosage and Administration

    The labeling adds one more hard constraint: the time between any two doses must be at least 3 days (72 hours). Every scenario below is just those two numbers — 4 days and 72 hours — applied to a calendar.

    Day-by-day: what to do based on how late you are

    Count from your scheduled injection day. If you normally inject on Sunday and it is now Tuesday, you are 2 days late.

    How late are you?Inside the 4-day window?What to do
    1 day lateYesInject now. Take your next dose on your regular day (a 6-day gap — fine).
    2 days lateYesInject now. Resume your regular day (a 5-day gap).
    3 days lateYesInject now. Resume your regular day (a 4-day gap).
    4 days lateYes — last dayInject now. Your regular day is 3 days away — exactly the label's 72-hour minimum, still allowed.
    5 or more days lateNoSkip the missed dose. Take your next dose on your regular day, at your usual dose. Do not double up.

    Why does the window close at exactly 4 days? A weekly cycle is 7 days. If you inject up to 4 days late and then return to your normal day, the gap between the late dose and the next one is at least 7 minus 4 — 3 days, precisely the label's 72-hour minimum. Past 4 days, resuming your normal schedule would put two doses closer together than 72 hours. The cutoff is not arbitrary; it is the spacing rule expressed as a deadline.

    Ask a provider, not a search bar

    Not sure which row you're in? Message a provider.

    Missed-dose math at 11pm is exactly what unlimited provider messaging is for. Trimi memberships include it — ask about your specific timeline before you inject anything you're unsure about. Clinician-guided compounded tirzepatide is $125/mo on the annual plan, all-inclusive, backed by a 6-month money-back policy. Individual results vary.

    Start your online visit

    Changing Your Injection Day After a Miss

    A missed dose often exposes a scheduling problem — Sunday injections that collide with travel, or a work rotation that changed. You do not have to force your way back to the old day. Per FDA prescribing information, the day of weekly administration can be changed as long as the time between two doses is at least 3 days (72 hours).

    In practice: if your last dose was Sunday and you want Thursdays going forward, inject Thursday (a 4-day gap) and stay weekly from there. Moving a day earlier works the same way — injecting one day early leaves a 6-day gap, comfortably inside the rule. The only forbidden move is compressing two doses into less than 72 hours.

    If you skipped a week under the 5-plus-days rule, that skipped week is a natural moment to reset your schedule to a day you will actually keep. Tell your provider about any permanent change so your refill and check-in cadence match your new calendar.

    What a Missed Week Actually Does in Your Body

    Tirzepatide has an elimination half-life of about 5 days per the label's clinical pharmacology data — that long tail is what makes once-weekly dosing possible in the first place. When you miss a dose, drug levels do not fall off a cliff. They decline by roughly half every 5 days, and it takes around 25 days for most of the drug to clear entirely.

    So a single missed week leaves you with meaningful — but falling — drug levels. Practically, that means appetite suppression fades gradually. Many people notice hunger creeping back toward the end of a missed week rather than the day after. It also means one late or skipped dose is very unlikely to undo your progress: in the SURMOUNT-1 trial, participants on the highest dose lost an average of 20.9% of body weight over 72 weeks of consistent weekly dosing (NEJM, 2022). Consistency over months is what produced that number, and individual results vary.

    Missed doses are also far more common than most people assume. According to a 2025 JAMA Network Open cohort study of US adults with overweight or obesity, 64.8% of patients without type 2 diabetes stopped their GLP-1 medication within one year — and interrupted or irregular dosing is often the first step in that pattern. Having a plan for the inevitable missed week is part of staying on therapy.

    One caution for the restart: some GI tolerance tracks steady drug exposure, so nausea, diarrhea, vomiting, or constipation — the most common side effects per FDA labeling — can flare again when you resume after a gap, even at your usual dose. Tirzepatide also carries less common but serious risks, including pancreatitis and gallbladder disease, and a boxed warning for thyroid C-cell tumors observed in rodent studies. If restarting feels notably rougher than your normal week-to-week experience, tell your provider rather than pushing through.

    Missed Two or More Weeks? Don't Restart on Your Own

    The FDA label defines the 4-day rule for a single missed dose. It does not define a restart protocol after an extended gap — because after several weeks off, the right answer depends on you: how long the gap was, what dose you had reached, and how you tolerated it.

    Here is the issue. Tirzepatide is titrated stepwise from 2.5 mg up to a maximum of 15 mg precisely so your GI tract can adapt (see our tirzepatide dosing chart for the full FDA schedule). During a multi-week gap, some of that adaptation fades while your last prescribed dose stays on the label of your medication. Jumping straight back in at a higher maintenance dose after weeks away can bring back the nausea and vomiting of the early titration weeks — or worse.

    Providers commonly restart at a lower dose and re-escalate, but the specific numbers are an individualized clinical call. We deliberately do not publish restart doses here: message your provider, tell them exactly how many weeks you missed and what dose you were on, and let them set the re-entry plan.

    Accidentally Took Tirzepatide Twice? What to Expect

    The mirror-image mistake: you forgot that you already injected, or two schedule changes collided, and you took two doses within a few days of each other. Because of the roughly 5-day half-life, the overlap does not clear quickly — expect the possibility of amplified side effects for several days, most commonly nausea, vomiting, diarrhea, and a strong loss of appetite.

    Serious hypoglycemia is unlikely from tirzepatide alone. The risk rises mainly if you also take insulin or a sulfonylurea — per FDA prescribing information, combining tirzepatide with an insulin secretagogue or insulin increases the risk of hypoglycemia, including severe hypoglycemia. If that describes you, monitor your blood sugar closely and contact your prescriber the same day.

    For everyone: hydrate, keep meals small and bland, and skip your next scheduled dose only if your provider tells you to. Call your provider or pharmacy promptly, and for immediate guidance call Poison Help at 1-800-222-1222. Seek urgent care for repeated vomiting or inability to keep fluids down, signs of dehydration, severe abdominal pain — especially pain radiating to your back, which can signal pancreatitis — or hypoglycemia symptoms like shakiness, sweating, or confusion. Our full walkthrough of the double-dose scenario is here: what to do after a GLP-1 double dose.

    Compounded Tirzepatide Vials: Same Principles, One Extra Trap

    The 4-day and 72-hour figures above come from the FDA labeling for Zepbound and Mounjaro. Compounded tirzepatide is prepared per individual prescription by a state-licensed pharmacy and is not FDA-approved as a drug, so your dispensing pharmacy's written instructions and your provider's directions govern your prescription. In practice they generally mirror the same weekly framework — but if your paperwork says something different, the paperwork wins.

    The vial-specific trap: with a pen, a missed week cannot change your dose — the device dials the same amount every time. With a vial and syringe, it can. Never "catch up" after a missed week by drawing more units than prescribed. A larger number on the syringe is a dose increase, not a correction, and the label's rules assume your usual dose on every injection. If you are ever unsure what your prescribed units look like on your syringe, our guide to reading syringe markings walks through it.

    One more check before restarting: if your missed week happened because life got chaotic — travel, a move, a delayed delivery — confirm your medication was stored properly during the gap before injecting from it. Here is how long a GLP-1 stays good outside the fridge. And if you want the full picture of how a clinician-guided compounded tirzepatide program handles dosing questions like these, see our tirzepatide treatment page.

    Frequently Asked Questions

    What should I do if I missed my tirzepatide dose?

    Per FDA prescribing information for Zepbound and Mounjaro, take the missed dose as soon as possible within 4 days (96 hours) of your scheduled injection day, then return to your regular weekly day. If more than 4 days have passed, skip the missed dose entirely and take your next dose on the regularly scheduled day. Never inject two doses less than 3 days (72 hours) apart, and never take a double dose to make up for a missed one. If you are unsure which situation you are in, message your provider before injecting.

    I missed my Mounjaro or Zepbound dose by 5 days. Can I still take it?

    No. Five days is outside the 4-day (96-hour) window in the FDA labeling. Skip the missed dose and take your next dose on your regularly scheduled day, at your usual prescribed dose. Do not take the late dose and the scheduled dose close together, and do not increase the next dose to compensate — the label's minimum spacing between any two doses is 3 days (72 hours).

    Can I take tirzepatide a day early?

    Usually yes. Per the FDA labeling, the day of weekly administration can be changed as long as the time between two doses is at least 3 days (72 hours). Injecting one day early leaves a 6-day gap, which is well inside that rule. If you want to permanently move your injection day — for travel or a new work schedule — keep at least 72 hours between the last dose on the old day and the first dose on the new day, then stay weekly from there. Confirm any recurring schedule change with your provider.

    What happens if I accidentally take tirzepatide twice in one week?

    Because tirzepatide has a half-life of about 5 days, two overlapping doses can amplify side effects for several days — most commonly nausea, vomiting, diarrhea, and reduced appetite. The risk of low blood sugar rises mainly if you also take insulin or a sulfonylurea. Contact your provider or pharmacy promptly, and call Poison Help at 1-800-222-1222 for guidance. Seek urgent care for repeated vomiting, inability to keep fluids down, signs of dehydration, severe abdominal pain (especially radiating to the back), or symptoms of hypoglycemia such as shakiness, sweating, or confusion.

    Will missing one tirzepatide dose make me regain weight?

    One missed week is very unlikely to erase your progress. Tirzepatide's roughly 5-day half-life means drug levels taper gradually rather than dropping to zero — appetite effects fade over days to weeks, not overnight. Follow the 4-day rule to get back on schedule, and expect that hunger may feel somewhat stronger until levels rebuild. Consistent weekly dosing is what drove results in clinical trials, and individual results vary.

    Do the same missed-dose rules apply to compounded tirzepatide?

    The 4-day rule comes from the FDA labeling for Zepbound and Mounjaro. Compounded tirzepatide is prepared per individual prescription by a state-licensed pharmacy and is not FDA-approved as a drug, so your dispensing pharmacy's instructions and your provider's directions govern your prescription — in practice they generally mirror the same weekly framework. The one vial-specific rule: never draw extra units to catch up after a missed week. A larger number on the syringe is a dose increase, not a correction.

    Judgment Calls Like This Are What Provider Messaging Is For

    Every Trimi membership includes unlimited messaging with licensed providers — so "how late is too late?" gets answered by a clinician who knows your chart, not a comment thread. Compounded tirzepatide is $125/mo on the annual plan, prepared by state-licensed partner pharmacies, with free overnight shipping once compounded and a 6-month money-back policy.

    Start your online visit

    Sources & References

    1. FDA Prescribing Information, Zepbound (tirzepatide) injection — Section 2, Dosage and Administration (missed dose; administration day change).
    2. FDA Prescribing Information, Mounjaro (tirzepatide) injection — Section 2, Dosage and Administration; Warnings and Precautions (hypoglycemia with insulin secretagogues or insulin).
    3. FDA Prescribing Information, Zepbound/Mounjaro (tirzepatide) — Section 12.3, Clinical Pharmacology (elimination half-life of approximately 5 days).
    4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205-216.
    5. Rodriguez PJ et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open, 2025.
    6. Farzam K, Patel P. Tirzepatide. StatPearls, NCBI Bookshelf — pharmacokinetics and steady-state dosing.
    7. America's Poison Centers — Poison Help Line, 1-800-222-1222.

    What does the published clinical evidence show for compounded tirzepatide?

    Peer-reviewed evidence: Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022). Trimi offers compounded tirzepatide starting at $125/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx, Texas pharmacy license #35264, and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively., SURMOUNT-1, NEJM 2022
    In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg., SURPASS-2, NEJM 2021
    Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo., SURMOUNT-OSA, NEJM 2024

    Key Takeaways

    • Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022)
    • In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. (Source: SURPASS-2, NEJM 2021)
    • Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. (Source: SURMOUNT-OSA, NEJM 2024)
    • The brand finished products (Zepbound and Mounjaro) are FDA-approved and manufactured at commercial scale. Trimi's compounded tirzepatide is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: August 7, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    - Veronica LarimoreFacebook
    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2107519
    3. Wadden TA, Chao AM, Machineni S, et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-023-02597-w
    4. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2023.24945
    5. Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2404881
    6. U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) Prescribing Information. FDA.Read Study

    Was this article helpful?

    Keep Reading

    Clinician-reviewed guide to tirzepatide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded tirzepatide option compares.

    Clinician-reviewed guide to tirzepatide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded tirzepatide option compares.

    Clinician-reviewed guide to tirzepatide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded tirzepatide option compares.

    Tirzepatide slows gastric emptying most 24-48 hours after each weekly dose, tapering over 7 days. See the dose-by-dose timeline and how to manage GI side effects.

    Start your GLP-1 journey, from $99/mo

    Get Started